bluebird bio, Inc. (BLUE) has a consensus analyst rating of Hold, based on 37 analysts covering the stock. Of those, 14 recommend buying, 19 recommend holding, and 4 recommend selling.
The analyst consensus price target for BLUE is $13.69, representing a +175.5% upside from the current price of $4.97. Price targets range from a low of $5.00 to a high of $25.00.
